Business
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on May 14, 2026. The annual report can be accessed on the Company's investor r
About this update from Jyong Biotech Ltd.
[{"type":"image","alt":"Jyong Biotech Ltd.","displaySize":"","headline":null,"caption":"Jyong Biotech Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/4d02bf8bdf07c2a180b8d0cc11d0b5eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EhHINnVTz5XZOfUzIB_fuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNg--/https://media.zenfs.com/en/globenewswire.com/4d02bf8bdf07c2a180b8d0cc11d0b5eb","width":250,"height":81},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/EhHINnVTz5XZOfUzIB_fuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNg--/https://media.zenfs.com/en/globenewswire.com/4d02bf8bdf07c2a180b8d0cc11d0b5eb","width":250,"height":81}},"lazy":false},{"type":"text","content":"New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on May 14, 2026.","length":448,"tagName":"p"},{"type":"text","content":"The annual report can be accessed on the Company's investor relations website at https://jyongir.com/ as well as the SEC's website at http://www.sec.gov.","length":176,"tagName":"p"},{"type":"text","content":"The Company will provide a hard copy of annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company at [email protected] .","length":235,"tagName":"p"},{"type":"text","content":"About Jyong Biotech Ltd.","length":24,"tagName":"p"},{"type":"text","content":"Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, ...